ArticleCureus2025
Association Between Metabolic Syndrome and Choledocholithiasis: An Observational, Analytical, Retrospective Cross-Sectional Study Conducted at a Second-Level Hospital in Ciudad Juárez From January 2024 to February 2025.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Metabolic syndrome (MS) is a disorder that groups conditions such as central obesity, hypertension, dyslipidemia, and hyperglycemia, and it is also associated with cardiovascular diseases and type 2 diabetes mellitus, in which an increase in biliary diseases such as choledocholithiasis, characterized by the presence of stones in the common bile duct, has been observed. This association may be explained by metabolic alterations that lead to increased cholesterol saturation in bile and impaired gallbladder motility due to insulin resistance, both of which contribute to the formation of stones. This study aims to investigate the relationship between MS and choledocholithiasis in patients treated at a second-level hospital in Ciudad Juárez between January 2024 and February 2025. Materials and methods Observational, analytical, retrospective, cross-sectional study with 59 patients over 17 years of age who were divided into two groups: with choledocholithiasis (29, 49%) and without choledocholithiasis (30, 51%). For each group, the ATP III diagnostic criteria for MS were evaluated. For statistical analysis, chi-square, Fisher's exact test, and odds ratio were used. Results The presence of MS was significantly associated with choledocholithiasis (p=0.002; OR=5.83, 95% CI: 1.93-19.33); BMI over 30 was the only MS component with a statistically significant association in both patients with and without choledocholithiasis (p=0.0016 and p=0.008, respectively). Conclusions The presence of MS is a risk factor for the development of choledocholithiasis in the studied population. A high BMI is confirmed as a relevant risk factor. These findings provide useful local evidence for the development of preventive strategies and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.